Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

FORTUNE O ALABI

Allopathic & Osteopathic Physicians Internal Medicine Critical Care Medicine

NPI
1124025309
CMS profile
5179
Location
KISSIMMEE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$81,424.08

282 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 6; records 101–150 of 282 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

FORTUNE O ALABI

NPI 1124025309 · CMS profile ID 5179

Allopathic & Osteopathic Physicians / Internal Medicine / Critical Care Medicine

KISSIMMEE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 6; records 101–150 of 282 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1124025309?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
FORTUNE O ALABI, NPI 1124025309, CMS profile ID 5179. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 282 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124025309?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). FORTUNE O ALABI, NPI 1124025309, CMS profile ID 5179. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 282 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124025309?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
FORTUNE O ALABI, NPI 1124025309, CMS profile ID 5179, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 6; records 101–150 of 282 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1124025309?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

282 matching records · $81,424.08 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 282 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 282.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $5.9308/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190839339 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $23.8108/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222733182 CMS
Insmed, Inc. $26.5708/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186314149 CMS
Actelion Pharmaceuticals US, Inc. $24.4408/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174201647 CMS
GlaxoSmithKline, LLC. $19.6008/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191227091 CMS
Actelion Pharmaceuticals US, Inc. $31.6008/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174201334 CMS
United Therapeutics Corporation $138.0208/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242530762 CMS
ANI Pharmaceuticals, Inc. $98.0008/01/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1248614594 CMS
ANI Pharmaceuticals, Inc. $2,700.0008/01/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1248630256 CMS
AstraZeneca Pharmaceuticals LP $15.8807/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206792121 CMS
Insmed, Inc. $26.5707/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186311882 CMS
United Therapeutics Corporation $134.5407/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242551856 CMS
AstraZeneca Pharmaceuticals LP $19.3307/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206177012 CMS
AstraZeneca Pharmaceuticals LP $124.7407/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207075127 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $19.8007/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222733180 CMS
GlaxoSmithKline, LLC. $12.3007/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191776539 CMS
AstraZeneca Pharmaceuticals LP $21.6407/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206393813 CMS
Axsome Therapeutics, Inc. $19.3207/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235398768 CMS
United Therapeutics Corporation $142.0207/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242530692 CMS
VERTEX PHARMACEUTICALS INCORPORATED $119.5007/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213925378 CMS
Insmed, Inc. $17.3807/18/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1186268920 CMS
Regeneron Healthcare Solutions, Inc. $3.0107/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212859478 CMS
Regeneron Healthcare Solutions, Inc. $36.5007/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212859480 CMS
Sandoz Inc. $16.2107/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1181971728 CMS
ANI Pharmaceuticals, Inc. $353.0007/17/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1248651626 CMS
ANI Pharmaceuticals, Inc. $2,700.0007/17/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1248652965 CMS
Grifols USA, LLC $26.2007/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249589497 CMS
Regeneron Healthcare Solutions, Inc. $8.5107/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212859476 CMS
Insmed, Inc. $26.5707/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186308192 CMS
Mallinckrodt Hospital Products Inc. $13.2507/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211947240 CMS
JAZZ PHARMACEUTICALS INC. $37.9507/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234315705 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $4.5407/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222733176 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $22.2607/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222733178 CMS
AstraZeneca Pharmaceuticals LP $1,850.0007/09/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1206167484 CMS
AstraZeneca Pharmaceuticals LP $1,850.0007/03/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1206598018 CMS
AstraZeneca Pharmaceuticals LP $19.7007/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207176807 CMS
AstraZeneca Pharmaceuticals LP $21.2407/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206569281 CMS
Takeda Pharmaceuticals U.S.A., Inc. $24.0207/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223889441 CMS
Verona Pharma, Inc. $8.9306/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233748637 CMS
AstraZeneca Pharmaceuticals LP $16.9306/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206418206 CMS
ANI Pharmaceuticals, Inc. $108.7806/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248583091 CMS
AstraZeneca Pharmaceuticals LP $124.5006/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206903595 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $1,800.0006/24/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1222733254 CMS
GlaxoSmithKline, LLC. $7.8706/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190605663 CMS
Actelion Pharmaceuticals US, Inc. $25.7306/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174201535 CMS
Regeneron Healthcare Solutions, Inc. $1.8606/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212859470 CMS
Regeneron Healthcare Solutions, Inc. $3.5806/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212859472 CMS
Regeneron Healthcare Solutions, Inc. $9.8706/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212859474 CMS
United Therapeutics Corporation $18.0306/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242558557 CMS
GlaxoSmithKline, LLC. $23.5206/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191265623 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $65,083.50 298
PY2020 $45,672.69 224
PY2021 $70,049.24 291
PY2022 $130,646.37 322
PY2023 $96,809.04 317
PY2024 $97,648.34 301
PY2025 $81,424.08 282

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,081,614.25 273
PY2024 Principal investigator $412,429.80 105
PY2023 Principal investigator $292,193.10 31
PY2022 Recipient $2,007.97 3
PY2022 Principal investigator $476,702.71 107
PY2021 Principal investigator $216,369.96 215
PY2020 Principal investigator $23,505.46 4
PY2019 Principal investigator $111,963.80 44

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

273 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $182.25 12/24/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184279978
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $641.25 12/24/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184279980
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $125.00 12/24/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184279982
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $125.00 12/24/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184279984
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $125.00 12/24/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184279986
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $239.83 12/19/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184277884
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $808.00 12/16/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220797301
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 12/15/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184275271
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 12/15/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184275273
Principal investigator 1 GENZYME CORPORATION $2,398.00 12/08/2025 Non-covered Recipient Entity
Clinical Research Specialists Llc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226114172
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,000.00 12/05/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220797309
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,000.00 12/05/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220797335
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,886.00 12/03/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220797331
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 12/01/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220672892
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 12/01/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220672894
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $125.00 11/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184266915
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 11/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184266917
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 11/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184266919
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 11/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184266921
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 11/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184266923
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 11/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184266925
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 11/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184266927
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $850.00 11/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184266929
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $50.00 11/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184266931
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,504.95 11/19/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184262761
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 11/01/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220672888
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 11/01/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220672890
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 10/27/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220672896
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,559.40 10/27/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220797299
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,282.40 10/21/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797259
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $239.83 10/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184251149
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $239.83 10/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184251151
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,278.42 10/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS, LLC
A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) No dispute reported 06/30/2026 1185540721
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 10/01/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220672884
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 10/01/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220672886
Principal investigator 1 Boehringer Ingelheim International GmbH $43.52 10/01/2025 Non-covered Recipient Entity
Florida Lung Asthma And Sleep Specialists
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220746112
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.47 09/29/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184244391
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 09/24/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220672882
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $400.00 09/24/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797257
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $250.00 09/23/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220797297
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $98.24 09/23/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220797329
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 09/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184239832
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.98 09/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184239834
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.98 09/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184239836
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,461.92 09/15/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184237526
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,737.00 09/08/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797251
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $44.92 09/04/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797253
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $450.00 09/04/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797255
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 09/01/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220672868
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 09/01/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220672870
Principal investigator 1 Boehringer Ingelheim International GmbH $43.52 09/01/2025 Non-covered Recipient Entity
Florida Lung Asthma And Sleep Specialists
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220746104
Principal investigator 1 Boehringer Ingelheim International GmbH $104.94 08/26/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220672874
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 08/26/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220672876
Principal investigator 1 Boehringer Ingelheim International GmbH $3.36 08/26/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220672878
Principal investigator 1 Boehringer Ingelheim International GmbH $3.00 08/26/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220672880
Principal investigator 1 Boehringer Ingelheim International GmbH $23.32 08/26/2025 Non-covered Recipient Entity
Florida Lung Asthma And Sleep Specialists
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220746106
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 08/26/2025 Non-covered Recipient Entity
Florida Lung Asthma And Sleep Specialists
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220746108
Principal investigator 1 Boehringer Ingelheim International GmbH $32.85 08/26/2025 Non-covered Recipient Entity
Florida Lung Asthma And Sleep Specialists
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220746110
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,263.70 08/18/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220797293
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,020.00 08/18/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220797295
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $500.00 08/14/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220797323
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,500.00 08/14/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220797325
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $500.00 08/13/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797241
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $189.00 08/13/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797243
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,500.00 08/13/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797245
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $200.00 08/13/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797247
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $134.03 08/11/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220797327
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $180.00 08/08/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797249
Principal investigator 1 GENZYME CORPORATION $500.00 08/04/2025 Non-covered Recipient Entity
Clinical Research Specialists Llc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226114165
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 08/01/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220672864
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 08/01/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220672866
Principal investigator 1 Boehringer Ingelheim International GmbH $43.52 08/01/2025 Non-covered Recipient Entity
Florida Lung Asthma And Sleep Specialists
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220746102
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,475.00 08/01/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220797321
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $875.00 07/30/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220797287
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,504.00 07/30/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220797289
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,336.00 07/30/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220797291
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 07/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220672872
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.47 07/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184221114
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 07/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184221152
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.25 07/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184221154
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $641.25 07/25/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184220238
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $182.25 07/25/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184220242
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $125.00 07/25/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184220246
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $125.00 07/25/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184220250
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.98 07/25/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184220252
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $125.00 07/25/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184220254
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,500.00 07/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184218023
Principal investigator 1 GENZYME CORPORATION $1,366.00 07/14/2025 Non-covered Recipient Entity
Clinical Research Specialists Llc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226114161
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $239.83 07/14/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184214918
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 07/01/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220672860
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 07/01/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220672862
Principal investigator 1 Boehringer Ingelheim International GmbH $43.52 07/01/2025 Non-covered Recipient Entity
Florida Lung Asthma And Sleep Specialists
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220746100
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $125.00 06/30/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184212003
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 06/30/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184212009
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.98 06/30/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184212035
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25.98 06/30/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184212037
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 06/30/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184212049
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $475.00 06/30/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184212081
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $239.83 06/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184211665
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,381.59 06/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184211803
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,424.63 06/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184211825
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,483.00 06/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184211833
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,989.24 06/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184211919
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,106.28 06/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184211931
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,500.00 06/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184211939
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,500.00 06/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184211973
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,200.50 06/24/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220797283
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,500.00 06/20/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220797271
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,950.00 06/20/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220797273
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,848.22 06/20/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220797275
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,050.00 06/20/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220797277
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,000.00 06/20/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220797279
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,000.00 06/20/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220797281
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $871.00 06/11/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220797307
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $13,500.00 06/09/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220797305
Principal investigator 1 GENZYME CORPORATION $21,482.00 06/09/2025 Non-covered Recipient Entity
Clinical Research Specialists Llc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226114145
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $900.00 06/06/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220797303
Principal investigator 1 GlaxoSmithKline, LLC. $3,500.00 06/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192125978
Principal investigator 1 GlaxoSmithKline, LLC. $12,000.00 06/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192125984
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 06/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROU No dispute reported 06/30/2026 1192130951
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $13,500.00 06/03/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220797333
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 06/01/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220672850
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 06/01/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220672852
Principal investigator 1 Boehringer Ingelheim International GmbH $43.52 06/01/2025 Non-covered Recipient Entity
Florida Lung Asthma And Sleep Specialists
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220746098
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 05/27/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220672858
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 05/27/2025 Non-covered Recipient Entity
Florida Lung Asthma And Sleep Specialists
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220746124
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 05/27/2025 Non-covered Recipient Entity
Florida Lung Asthma And Sleep Specialists
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220746126
Principal investigator 1 Boehringer Ingelheim International GmbH $244.28 05/27/2025 Non-covered Recipient Entity
Florida Lung Asthma And Sleep Specialists
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220746128
Principal investigator 1 Boehringer Ingelheim International GmbH $82.92 05/27/2025 Non-covered Recipient Entity
Florida Lung Asthma And Sleep Specialists
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220746130
Principal investigator 1 Boehringer Ingelheim International GmbH $6.72 05/27/2025 Non-covered Recipient Entity
Florida Lung Asthma And Sleep Specialists
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220746132
Principal investigator 1 Boehringer Ingelheim International GmbH $28.00 05/27/2025 Non-covered Recipient Entity
Florida Lung Asthma And Sleep Specialists
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220746134
Principal investigator 1 GENZYME CORPORATION $1,888.00 05/19/2025 Non-covered Recipient Entity
Clinical Research Specialists Llc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226114155
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,000.00 05/17/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220797285
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $24,500.70 05/09/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220797267
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $172.34 05/09/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220797319
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $28.00 05/02/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220797269
Principal investigator 1 Boehringer Ingelheim International GmbH $3.86 05/01/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220672846
Principal investigator 1 Boehringer Ingelheim International GmbH $34.63 05/01/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220672848
Principal investigator 1 Boehringer Ingelheim International GmbH $43.52 05/01/2025 Non-covered Recipient Entity
Florida Lung Asthma And Sleep Specialists
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220746096
Principal investigator 1 Insmed, Inc. $21.71 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646696
Principal investigator 1 Insmed, Inc. $119.73 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646698
Principal investigator 1 Insmed, Inc. $21.71 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646700
Principal investigator 1 Insmed, Inc. $124.28 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646702
Principal investigator 1 Insmed, Inc. $147.94 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646704
Principal investigator 1 Insmed, Inc. $134.68 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646706
Principal investigator 1 Insmed, Inc. $152.88 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646708
Principal investigator 1 Insmed, Inc. $135.33 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646710
Principal investigator 1 Insmed, Inc. $152.88 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646712
Principal investigator 1 Insmed, Inc. $22.75 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646714
Principal investigator 1 Insmed, Inc. $22.75 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646716
Principal investigator 1 Insmed, Inc. $22.75 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646718
Principal investigator 1 Insmed, Inc. $4.16 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646720
Principal investigator 1 Insmed, Inc. $4.16 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646722
Principal investigator 1 Insmed, Inc. $9.75 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646724
Principal investigator 1 Insmed, Inc. $22.75 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646726
Principal investigator 1 Insmed, Inc. $22.75 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646728
Principal investigator 1 Insmed, Inc. $4.16 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646730
Principal investigator 1 Insmed, Inc. $135.33 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646732
Principal investigator 1 Insmed, Inc. $126.23 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646734
Principal investigator 1 Insmed, Inc. $21.71 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646736
Principal investigator 1 Insmed, Inc. $21.71 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646738
Principal investigator 1 Insmed, Inc. $141.18 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646740
Principal investigator 1 Insmed, Inc. $137.02 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646742
Principal investigator 1 Insmed, Inc. $21.71 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646744
Principal investigator 1 Insmed, Inc. $119.73 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646746
Principal investigator 1 Insmed, Inc. $21.71 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646748
Principal investigator 1 Insmed, Inc. $124.28 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646750
Principal investigator 1 Insmed, Inc. $124.28 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646752
Principal investigator 1 Insmed, Inc. $147.94 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646754
Principal investigator 1 Insmed, Inc. $122.07 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646756
Principal investigator 1 Insmed, Inc. $21.71 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646758
Principal investigator 1 Insmed, Inc. $134.68 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646760
Principal investigator 1 Insmed, Inc. $152.88 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646762
Principal investigator 1 Insmed, Inc. $135.33 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646764
Principal investigator 1 Insmed, Inc. $126.23 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646766
Principal investigator 1 Insmed, Inc. $21.71 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646768
Principal investigator 1 Insmed, Inc. $21.71 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646770
Principal investigator 1 Insmed, Inc. $141.18 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646772
Principal investigator 1 Insmed, Inc. $137.02 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646774
Principal investigator 1 Insmed, Inc. $141.83 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646776
Principal investigator 1 Insmed, Inc. $1,000.00 04/28/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189646778
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.47 04/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
REGISTRY OF ASTHMA PATIENTS INITIATING DUPIXENT (RAPID) No dispute reported 06/30/2026 1184190237
Principal investigator 1 Boehringer Ingelheim International GmbH $58.30 04/23/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220672854
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 04/23/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220672856
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $781.45 04/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184185689
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $300.00 04/22/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220797317
Principal investigator 1 AstraZeneca Pharmaceuticals LP $15,127.60 04/09/2025 Non-covered Recipient Entity
AGA CLINICAL TRIALS
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185540719
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,926.60 04/09/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220797315
Principal investigator 1 Boehringer Ingelheim International GmbH $43.52 04/01/2025 Non-covered Recipient Entity
Florida Lung Asthma And Sleep Specialists
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220746094
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7.33 04/01/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797239
Principal investigator 1 Boehringer Ingelheim International GmbH $46.64 03/25/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220672838
Principal investigator 1 Boehringer Ingelheim International GmbH $365.00 03/25/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220672840
Principal investigator 1 Boehringer Ingelheim International GmbH $16.80 03/25/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220672842
Principal investigator 1 Boehringer Ingelheim International GmbH $15.00 03/25/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220672844
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,381.50 03/25/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220797265
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220672914
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220672916
Principal investigator 1 Boehringer Ingelheim International GmbH $103.87 03/01/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220672918
Principal investigator 1 Boehringer Ingelheim International GmbH $11.57 03/01/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220672920
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220672926
Principal investigator 1 Boehringer Ingelheim International GmbH $43.52 03/01/2025 Non-covered Recipient Entity
Florida Lung Asthma And Sleep Specialists
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220746082
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22.00 03/01/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797189
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 02/25/2025 Non-covered Recipient Entity
Florida Lung Asthma And Sleep Specialists
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220746116
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 02/25/2025 Non-covered Recipient Entity
Florida Lung Asthma And Sleep Specialists
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220746118
Principal investigator 1 Boehringer Ingelheim International GmbH $3.36 02/25/2025 Non-covered Recipient Entity
Florida Lung Asthma And Sleep Specialists
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220746120
Principal investigator 1 Boehringer Ingelheim International GmbH $10.00 02/25/2025 Non-covered Recipient Entity
Florida Lung Asthma And Sleep Specialists
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220746122
Principal investigator 1 Boehringer Ingelheim International GmbH $23.30 02/24/2025 Non-covered Recipient Entity
Florida Lung Asthma And Sleep Specialists
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220746078
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,601.50 02/14/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220797263
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $200.00 02/07/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797181
Principal investigator 1 GlaxoSmithKline, LLC. $1,023.00 02/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192126028
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $200.00 02/06/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797193
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,100.00 02/06/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797195
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $200.00 02/06/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797197
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $200.00 02/06/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797199
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,259.00 02/06/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797201
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,018.00 02/06/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797203
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $200.00 02/06/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797205
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,200.00 02/06/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797207
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $200.00 02/06/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797209
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,100.00 02/06/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797211
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,811.00 02/06/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797213
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $200.00 02/06/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797215
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $200.00 02/06/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797217
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $200.00 02/06/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797219
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $200.00 02/06/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797221
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $200.00 02/06/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797223
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,918.00 02/06/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797225
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $200.00 02/06/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797227
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,200.00 02/06/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797229
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,583.00 02/06/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797231
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $200.00 02/06/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797233
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $200.00 02/06/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797235
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $80.00 02/06/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797237
Principal investigator 1 GENZYME CORPORATION $1,366.00 02/04/2025 Non-covered Recipient Entity
Clinical Research Specialists Llc
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226114134
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220672906
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220672908
Principal investigator 1 Boehringer Ingelheim International GmbH $11.57 02/01/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220672910
Principal investigator 1 Boehringer Ingelheim International GmbH $103.87 02/01/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220672912
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220672924
Principal investigator 1 Boehringer Ingelheim International GmbH $43.52 02/01/2025 Non-covered Recipient Entity
Florida Lung Asthma And Sleep Specialists
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220746080
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22.00 02/01/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797187
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,926.60 02/01/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797191
Principal investigator 1 AstraZeneca Pharmaceuticals LP $62,303.54 01/29/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS, LLC
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185540723
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 01/27/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220672832
Principal investigator 1 Boehringer Ingelheim International GmbH $8.40 01/27/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220672834
Principal investigator 1 Boehringer Ingelheim International GmbH $7.50 01/27/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220672836
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 01/27/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220672928
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 01/27/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220672930
Principal investigator 1 Boehringer Ingelheim International GmbH $28.04 01/27/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220672932
Principal investigator 1 Boehringer Ingelheim International GmbH $13.32 01/27/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220672934
Principal investigator 1 Boehringer Ingelheim International GmbH $13.32 01/27/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220672936
Principal investigator 1 Boehringer Ingelheim International GmbH $13.32 01/27/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220672938
Principal investigator 1 Boehringer Ingelheim International GmbH $13.32 01/27/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220672940
Principal investigator 1 Boehringer Ingelheim International GmbH $3.20 01/27/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220672942
Principal investigator 1 Boehringer Ingelheim International GmbH $23.32 01/27/2025 Non-covered Recipient Entity
Florida Lung Asthma And Sleep Specialists
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220746084
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 01/27/2025 Non-covered Recipient Entity
Florida Lung Asthma And Sleep Specialists
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220746086
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 01/27/2025 Non-covered Recipient Entity
Florida Lung Asthma And Sleep Specialists
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220746088
Principal investigator 1 Boehringer Ingelheim International GmbH $32.85 01/27/2025 Non-covered Recipient Entity
Florida Lung Asthma And Sleep Specialists
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220746090
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,717.80 01/21/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220797313
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $267,039.69 01/13/2025 Non-covered Recipient Entity
Clinical Research Specialists, Llc
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1235998004
Principal investigator 1 GlaxoSmithKline, LLC. $2,399.40 01/13/2025 Non-covered Recipient Entity
CLINICAL RESEARCH SPECIALISTS LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192130957
Principal investigator 1 Boehringer Ingelheim International GmbH $116.48 01/09/2025 Non-covered Recipient Entity
Florida Lung Asthma And Sleep Specialists
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220746114
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $399,651.30 01/09/2025 Non-covered Recipient Entity
Florida Lung Asthma And Sleep Specialists, Pa
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis No dispute reported 06/30/2026 1235997317
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,389.90 01/07/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797183
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $7,435.80 01/06/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER-ON) No dispute reported 06/30/2026 1220797261
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $121.54 01/06/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) No dispute reported 06/30/2026 1220797311
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220672898
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220672900
Principal investigator 1 Boehringer Ingelheim International GmbH $11.57 01/01/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220672902
Principal investigator 1 Boehringer Ingelheim International GmbH $103.87 01/01/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
PDE4 Phase III trial in IPF patients No dispute reported 06/30/2026 1220672904
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
PDE4 Phase III trial in PF-ILD No dispute reported 06/30/2026 1220672922
Principal investigator 1 Boehringer Ingelheim International GmbH $43.52 01/01/2025 Non-covered Recipient Entity
Florida Lung Asthma And Sleep Specialists
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220746092
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22.00 01/01/2025 Non-covered Recipient Entity
Clinical Research Specialists LLC
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF) No dispute reported 06/30/2026 1220797185